Labordiagnostik bei SARS-CoV-2-Infektionen

Martin Roskos

doi:10.1055/a-1220-4425

Der Klinikarzt, Table of Contents

Der Klinikarzt 2020; 49(07/08): 292-298
DOI: 10.1055/a-1220-4425

Schwerpunkt

Labordiagnostik bei SARS-CoV-2-Infektionen

Erregeridentifizierung, Antikörperdiagnostik und Beurteilung des Krankheitsverlaufs

Martin Roskos

¹SYNLAB Medizinisches Versorgungszentrum Weiden GmbH Medizinisches Versorgungszentrum Gera SYNLAB Liquorzentrum Gera

› Author Affiliations

Abstract

ZUSAMMENFASSUNG

Die aktuelle COVID-19-Pandemie stellte auch die medizinischen Labore vor große Herausforderungen. Der prinzipiell sehr frühen Kenntnis des primär neuen Erregers und der prinzipiellen Möglichkeit des Nachweises des Virus stand oft eine zunächst unzureichende Verfügbarkeit an Reagenzien und Analysensystemen gegenüber, die aber relativ schnell verbessert werden konnten, sodass nun eine flächendeckende und schnelle Diagnostik dieses Erregers möglich ist. Neben der Erregeridentifizierung liefert die Labordiagnostik jedoch auch wichtige Hinweise bei der Beurteilung der Erkrankung bzw. der Abschätzung des weiteren Verlaufes. Die Wertigkeit einzelner Parameter bzw. Parameterkonstellationen wurde dabei teilweise erst im Verlauf der Pandemie deutlich bzw. ist auch noch in der Evaluierung.

Full Text

References

Literatur
1 Wang LF, Anderson DE, Mackenzie JS. et al From Hendra to Wuhan: what has been learned in responding. Lancet 2020; 295: e33-e34
2 Phillips N, Mallapaty S, Cyranosk Di. How quickly does the Wuhan virus spread?. Nature 2020 https://www.nature.com/articles/d41586-020-00146-w In: Nature. 21. Januar 2020, doi:10.1038/d41586-020-00146-w
3 Gorbalenya AE, Baker SC, Baric RS. et al Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. bioRxiv 2020 https://doi.org/10.1101/2020.02.07.937862
4 Roujian L, Xiang Z, Juan L. et al Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 565-574
5 Kuhn JH, Jahrling PB. Clarification and guidance on the proper usage of virus and virus species names. Arch Virol 2010; 155: 445-453
6 Delmas B, Laude H. Assembly of Coronavirus Spike Protein Into Trimers and Its Role in Epitope Expression. J Virol 1990; 64: 5367-5375
7 Wrapp D, Wang N, Corbett KC. et al Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367: 1260-1263
8 Yan R, Zhang Y, Li Y. et al Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444-1448
9 Biological.com, Sino Spike Protein/S Protein. https://www.sinobiological.com/research/virus/hcov-spike-protein-overview abgerufen am 29.06.2020
10 Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Molrcular Cell 2020; 78: 1-6
11 Wu F, Zhao S, Yu B. Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome. NCBI 2020 https://www.ncbi.nlm.nih.gov/nuccore/MN908947
12 Nucleotide, NCBI Database txid2697049 (Severe acute respiratory syndrome coronavirus 2). Website Nucleotide des National Center for Biotechnology Information (NCBI) https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049
13 Denison MR, Graham RL, Donaldson EF. et al Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. RNA Biology 2011; 8: 270-279
14 Anfinrud P, Bax CE, Stadnytskyi V, Bax A. et al Could SARS-CoV-2 be transmitted via speech droplets?. MedRxiv 2020 doi: https://doi.org/10.1101/2020.04.02.20051177
15 Anfinrud P, Stadnytskyi V, Bax CE, Bax A. Visualizing Speech-Generated Oral Fluid Droplets with Laser Light Scattering. New Engl J Med 2020; 382: 2061-2063
16 van Doremalen N, Bushmaker T, Morris DH. et al Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. New Engl J Med 2020; 382: 1564-1567
17 Stadnytskyia V, Baxb CE, Baxa A. et al The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. PNAS 2020; 117: 11875-11877
18 Fears AC, Klimstra WB, Duprex P. et al Comparative dynamic aerosol efficiencies of three emergent coronaviruses and the unusual persistence of SARS-CoV-2 in aerosol suspensions. medRxiv 2020 Preprint 2020 Apr 18 https://doi.org/10.1101/2020.04.13.20063784
19 Bourouiba L. Turbulent Gas Clouds and Respiratory Pathogen Emissions Potential Implications for Reducing Transmission of COVID-19. JAMA 2020; 323: 1837-1838
20 van der Hoek L. Human coronaviruses: what do they cause?. Antivir Ther 2007; 12: 651-658
21 Rockx B, Kuiken T, Sander Herfst S. et al Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 2020; 368: 1012-1015
22 Hassanin A. Coronavirus Could Be a ‘Chimera’ of Two Different Viruses, Genome Analysis Suggests. Science alert 2020 https://www.sciencealert.com/genome-analysis-of-the-coronavirus-suggests-two-viruses-may-have-combined
23 Sae TH. coronavirus-covid-19-not-human-made-lab-genetic-analysis-nature. ScienceNews 2020 https://www.sciencenews.org/article/coronavirus-covid-19-not-human-made-lab-genetic-analysis-nature
24 Li X, Giorgi EE, Marichannegowda MH. et al Emergence of SARS-CoV-2 through recombination and strong purifying selection. Science Advances 2020 Preprint 2020 Mar 22, doi:10.1126/sciadv.abb9153
25 Andersen KG, Rambaut A, Lipkin I. et al The proximal origin of SARS-CoV-2. Nature Medicine 2020; 26: 450-455
26 Deslandes A, Berti V, Tandjaoui-Lambotte Y. et al SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents 2020; 55: 106006
27 Corman V, Bleicker T, Sebastian Brünink S. et al Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR. https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2 (abgerufen am 29.06.2020)
28 Carter LJ, Garner LV, Jeffrey Smoot JW. et al Assay Techniques and Test Development for COVID-19 Diagnosis. ACS Cent Sci 2020; 6: 591-605
29 Nahapetyan K, Inbanathan F, Pereyaslov D. et al Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. WHO Interim guidance 2020 S. WHO/COVID-19/laboratory/2020.4
30 Bundesvereinigung, Kassenärztliche Einheitlicher Bewertungsmaßstab (EBM) Arztgruppen EBM Labormedizin. 2020 Stand 2/2020, erstellt am 05.06.2020
31 Broughton JP, Deng X, Yu G. et al CRISPR–Cas12-based detection of SARS-CoV-2. Nature Biotechnology 2020 https://doi.org/10.1038/s41587-020-0513-4
32 Wu Z, Jennifer M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-1242
33 Aylward B, Dong X, Eckmanns T. et al Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Organization, World Health 2020 https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
34 Huang C, Wang Y, Li X. et al Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506
35 Li H, Liu L, Zhang D. et al SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020; 395: 1517-1520
36 Spinato G, Fabbris C, Polesel J. et al Alterations in Smell or Taste in Mildly Symptomatic OutpatientsWith SARS-CoV-2 Infection. JAMA 2020; 323: 2089-2090
37 Institut, Robert Koch SARS-CoV-2 Steckbrief zur Coronavirus-Krankheit-2019 (COVID-19),. Stand 26.05.2020. 2020,/ www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Steckbrief.html#doc13776792bodyText5
38 van Kasteren PB, van der Veer B, van den Brink S. et al Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J Clin Virol 2020; 128: 104412
39 Wang D, Hu B, Hu C. et al Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia inWuhan, China. JAMA 2020; 323: 1061-1069
40 Koorak S, Hosseiny M, Myers L. et al Coronavirus (COVID-19) Outbreak: What the Department of Radiology Should Know. J Am Coll Radiol 2020; 17: 447-451
41 Prevention, Korea Center of Disease Control & Findings from Investigation and Analysis of re-positive Cases. 2020 https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030&act=view&list_no=367267&nPage=8
42 Wu J, Liu X, Liu J. et al Coronavirus Disease 2019 Test Results After Clinical Recovery and Hospital Discharge Among Patients in China. JAMA 2020; 5: e209759
43 Dreher M, Kersten A, Bickenbach J. et al Charakteristik von 50 hospitalisierten COVID-19-Patienten mit und ohne ARDS. Deutsches Ärzteblatt 2020; 117: 271-278
44 Shen C, Wang Z, Zhao F. et al Treatment of 5 Critically Ill Patients WithCOVID-19 With Convalescent Plasma. JAMA 2020; 323: 1582-1589
45 Wölfel R, Corman VM, Guggemos W. et al Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. medRxiv https://doi.org/10.1101/2020.03.05.20030502
46 Wölfel R, Corman VM, Guggemos W. et al Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581: 465-469
47 Helms J, Kremer S, Merdji H. et al Neurologic Features in Severe SARS-CoV-2 Infection. New Engl J Med 2020; 382: 2268-2270
48 Li D, Jin M, Bao P. et al Clinical Characteristics and Results of Semen Tests Among Men. JAMA Netw Open 2020; 3: e208292
49 Groß R, Conzelmann C, Müller JA. et al Detection of SARS-CoV-2 in human breastmilk. Lancet 2020; 395: 1757-1758
50 WHO https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html 2020
51 Streeck H, Schulte B, Kümmerer BM. et al Infection fatality rate of SARS-CoV-2 infection in a German. MEDRxiv 2020 S. Infection fatality rate of SARS-CoV-2 infection in a German https://doi.org/10.1101/2020.05.04.20090076
52 Bendavid E, Mulaney B, Sood N. et al COVID-19 Antibody Seroprevalence in Santa Clara County, California. medRxiv 2020 https://doi.org/10.1101/2020.04.14.20062463
53 Deeks JJ, Dinnes J, Takwoingi Y. et al Antibody tests for identification of current and past infection with SARS-CoV-2 (Review). Cochrane Database Syst Rev 2020; 6: CD013652
54 Steensels D, Oris E, Coninx L. et al Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. JAMA 2020; 324: 195-197
55 Long QX, Liu BT, Deng HJ. et al Antibody responses to SARS-CoV-2 in patients. Nature Medicine 2020; 26: 845-848
56 Padoana A, Sciacovellib L. Bassoa, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with. Clinica Chimica Acta 2020; 507: 164-166
57 Sethuraman N, Stanleyraj S, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA 2020 2020 May 6. doi: 10.1001/jama.2020.8259. Online ahead of print
58 Ballini L, Djuric O, Venturelli F. et al Rapid collaborative Review on the current Role of Antibody Tests for novel Coronavirus SarsC0V-2 in the Management of the Pandemic. European Network for Health Technology Assessment 2020 Project ID: RCR OT 01, Version 1.2, 22 Juni 2020 https://eunethta.eu/wp-content/uploads/2020/05/project_plan_antibody-tests-for-COVID-19_12-05-2020_FINAL.pdf
59 Bundesvereinigung, Kassenärztliche Coronavirus: Informationen für Ärzte, Psychotherapeuten und Praxisteams. 2020 https://www.kbv.de/html/coronavirus.php (abgerufen am 26.06.2020)
60 Young BE, Xiang SW, Kalimuddin S al et. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 2020; 323: 1488-1494
61 Wang D, Hu B, Hu C. Clinical Characteristics of 138 Hospitalized Patients Clinical Characteristics of 138 Hospitalized Patients. JAMA 2020; 323: 1061-1069
62 Guan W, Ni Z, Hu Y. et al Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl J Med 2020; 382: 1708-1720
63 Lippi G, Plebanib M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clinica Chimica Acta 2020; 505: 190-191
64 Lu X, Zhang L, Du H. et al SARS-CoV-2 Infection in Children. New Engl J Med 2020; 282: 1663-1665
65 Henry BM, Lippia G, Plebania M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med 2020; 58: 1135-1138
66 Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92: 1-4
67 Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S. et al Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology 2020 https://doi.org/10.1212/WNL.0000000000009619
68 Zhao H, Shen D, Zhou H. et al Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?. Lancet/Neurology 2020; 19: 383-384
69 Toscano G, Palmerini F, Ravaglia S. et al Guillain–Barré Syndrome Associated with SARS-CoV-2. New Engl J Med 2020; 20: e00771
70 Jiang X, Coffee M, Bari A. et al Towards an Artificial Intelligence Framework for Data-Driven Prediction of Coronavirus Clinical Severity. Computers, Materials & Continua 2020; 63: 537-551
71 Liang W, Liang H, Ou L. et al Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAM Intern Med 2020; May 12: e202033
72 Yan L, Zhang HT, Goncalves J. et al An interpretable mortality prediction model for COVID-19 patients. Nature Machine Intelligence 2020; 2: 283-288
73 Gross O, Moerer O, Weber M. et al COVID-19-associated nephritis: early warning for disease severity and complications?. Lancet 2020; 395: 287-288